Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Molecular mechanisms underlying synergistic adhesion of sickle red blood cells by hypoxia and low nitric oxide bioavailability.

Gutsaeva DR, Montero-Huerta P, Parkerson JB, Yerigenahally SD, Ikuta T, Head CA.

Blood. 2014 Mar 20;123(12):1917-26. doi: 10.1182/blood-2013-06-510180. Epub 2014 Jan 15.

2.

The proinflammatory cytokine GM-CSF downregulates fetal hemoglobin expression by attenuating the cAMP-dependent pathway in sickle cell disease.

Ikuta T, Adekile AD, Gutsaeva DR, Parkerson JB, Yerigenahally SD, Clair B, Kutlar A, Odo N, Head CA.

Blood Cells Mol Dis. 2011 Dec 15;47(4):235-42. doi: 10.1016/j.bcmd.2011.08.005. Epub 2011 Sep 25.

3.

Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms.

dos Santos JL, Lanaro C, Lima LM, Gambero S, Franco-Penteado CF, Alexandre-Moreira MS, Wade M, Yerigenahally S, Kutlar A, Meiler SE, Costa FF, Chung M.

J Med Chem. 2011 Aug 25;54(16):5811-9. doi: 10.1021/jm200531f. Epub 2011 Jul 25.

PMID:
21766854
4.

Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice.

Meiler SE, Wade M, Kutlar F, Yerigenahally SD, Xue Y, Moutouh-de Parseval LA, Corral LG, Swerdlow PS, Kutlar A.

Blood. 2011 Jul 28;118(4):1109-12. doi: 10.1182/blood-2010-11-319137. Epub 2011 May 2.

5.

Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease.

Gutsaeva DR, Parkerson JB, Yerigenahally SD, Kurz JC, Schaub RG, Ikuta T, Head CA.

Blood. 2011 Jan 13;117(2):727-35. doi: 10.1182/blood-2010-05-285718. Epub 2010 Oct 6.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk